Multi-organ Linkage Pathophysiology and Therapy for NAFLD and NASH

34.1K

views

86

authors

12

articles

Multi-organ Linkage Pathophysiology and Therapy for NAFLD and NASH

34.1K

views

86

authors

12

articles

Editorial

05 June 2024

Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH

Takefumi Kimura

,

Tomoo Yamazaki

and

Gabriel Rufino Estrela

412 views

0 citations

Editors

0

Impact

About

NAFLD and NASH refer to the hepatic phenotype of metabolic syndromes strongly associated with obesity, diabetes, and dyslipidemia. NAFLD and NASH have complex pathogenesis modulated not only by the liver but also by muscle, adipose tissue, pancreas, gut microbiome, and immune and central nervous systems. This complex pathology, coupled with insulin resistance, lipid and bile acid changes, and congenital genetic predisposition, induces liver injury due to oxidative stress, endoplasmic reticulum stress, and autophagy dysfunction. Additionally, NAFLD and NASH contribute to diseases such as cirrhosis, atherosclerosis, chronic kidney disease, lung disease, and cancer in various organs, leading to systemic multi-organ damage. Even though enthusiastic development of new drugs for NAFLD and NASH has been underway, we are still lacking progress in generating therapeutic agents based on multiorgan-related pathomechanisms. In this special issue, we welcome clinical and basic studies on extrahepatic lesions as well as new findings related to liver pathology in NAFLD and NASH. Topic Editors welcome manuscripts particularly focusing on new therapies and new signaling pathways on the multiorgan-linkage of NAFLD and NASH.

NAFLD and NASH refer to the hepatic phenotype of metabolic syndromes strongly associated with obesity, diabetes, and dyslipidemia. NAFLD and NASH have complex pathogenesis modulated not only by the liver but also by muscle, adipose tissue, pancreas, gut microbiome, and immune and central nervous systems. This complex pathology, coupled with insulin resistance, lipid and bile acid changes, and congenital genetic predisposition, induces liver injury due to oxidative stress, endoplasmic reticulum stress, and autophagy dysfunction. Additionally, NAFLD and NASH contribute to diseases such as cirrhosis, atherosclerosis, chronic kidney disease, lung disease, and cancer in various organs, leading to systemic multi-organ damage. Even though enthusiastic development of new drugs for NAFLD and NASH has been underway, we are still lacking progress in generating therapeutic agents based on multiorgan-related pathomechanisms. In this special issue, we welcome clinical and basic studies on extrahepatic lesions as well as new findings related to liver pathology in NAFLD and NASH. Topic Editors welcome manuscripts particularly focusing on new therapies and new signaling pathways on the multiorgan-linkage of NAFLD and NASH.

Share

Editors

Impact

34,077 Total views

18,814 Article views

14,160 Article downloads

1,103 Topic views

Published In

Frontiers in Endocrinology

Frontiers in Public Health

Frontiers in Nutrition

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic